Medline (MDLN) Stock Price, News & Analysis

Company Overview

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations. Its offerings typically include direct delivery, customized kit and procedure-packaging services, inventory management programs and value‑added services such as clinical education and operational consulting. These capabilities are aimed at improving clinical workflow and supporting large, complex supply networks.

Medline operates through an extensive distribution network and serves customers across multiple geographies, with a primary focus on North American healthcare markets alongside international sales and distribution activity. The company is run by an executive leadership team responsible for its commercial, operational and clinical service lines. As a company listed on the NASDAQ under the symbol MDLN, Medline positions itself as an integrated supplier and supply‑chain partner for the healthcare industry.

Key Stats

• Today's Range: $34.03 to $35.81
• 50-Day Range: $33.19 to $43.19
• 52-Week Range: $32.81 to $50.88
• Volume: 8.34 million shs
• Average Volume: 7.38 million shs
• Market Capitalization: $46.28 billion
• P/E Ratio: 110.09
• Dividend Yield: N/A
• Price Target: $48.50
• Consensus Rating: Moderate Buy

Medline Stock Analysis - MarketRank™

Medline scored higher than 91% of companies evaluated by MarketBeat, and ranked 46th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Medline has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 22 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Medline has a consensus price target of $48.50, representing about 37.2% upside from its current price of $35.36.

Amount of Analyst Coverage

Medline has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 7.38%

Earnings Growth

Earnings for Medline are expected to grow by 7.38% in the coming year, from $1.49 to $1.60 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medline is 110.54, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medline is 110.54, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.83.

Price to Earnings Growth Ratio

Medline has a PEG Ratio of 5.32. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Medline has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.26% of the float of Medline has been sold short.

Short Interest Ratio / Days to Cover

Medline has a short interest ratio ("days to cover") of 4.48.

Change versus previous month

Short interest in Medline has recently decreased by 18.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medline does not currently pay a dividend.

Dividend Growth

Medline does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.40

News Sentiment

Medline has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Medline this week, compared to 7 articles on an average week.

Search Interest

13 people have searched for MDLN on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.

MarketBeat Follows

11 people have added Medline to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Medline insiders have sold 2,053.44% more of their company's stock than they have bought. Specifically, they have bought $170,750.00 in company stock and sold $3,677,000.00 in company stock.

Percentage Held by Insiders

0.81% of the stock of Medline is held by insiders.

Percentage Held by Institutions

Medline has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:MDLN
• CIK: 2046386
• Web: N/A
• Phone: (847) 949-3000
• Fax: N/A
• Employees: 45,000
• Year Founded: 1966

Price Target and Rating

• Average Price Target for Medline: $48.50
• High Price Target: $62.00
• Low Price Target: $37.00
• Potential Upside/Downside: +37.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 29 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 110.09
• Forward P/E Ratio: 23.64
• P/E Growth: 5.32
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 4.41
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: $28.43 billion
• Price / Sales: 1.63
• Cash Flow: $1.63 per share
• Price / Cash Flow: 21.61
• Book Value: $14.68 per share
• Price / Book: 2.40

Miscellaneous

• Outstanding Shares: 1,313,690,000
• Free Float: 1,303,047,000
• Market Cap: $46.28 billion
• Optionable: N/A
• Beta: N/A